Clinical outcomes of upadacitinib dose escalation in inflammatory bowel disease: A single-center retrospective cohort study

Table 4 Symptom improvement in patients escalated for uncontrolled symptoms, n (%)

Symptom	Before, n = 30	After, n = 30	P value
Any symptoms	30 (100)	25 (83.3)	0.063
Abdominal pain	19 (63.3)	8 (26.7)	0.003
Urgency	15 (50.0)	7 (23.3)	0.077
Hematochezia	16 (53.3)	5 (16.7)	0.007
Diarrhea	19 (63.3)	12 (40.0)	0.039
Extra-intestinal manifestations	14 (46.7)	10 (33.3)	0.160
Mucus	4 (13.3)	2 (6.7)	0.625
Tenesmus	1 (3.3)	3 (10.0)	0.625
Constipation	3 (10.0)	2 (6.7)	1.000
Nausea	5 (16.7)	5 (16.7)	1.000
Vomiting	2 (6.7)	1 (3.3)	1.000

Gastrointestinal and extra-intestinal symptoms were documented among patients escalated for uncontrolled symptoms. P values were calculated using McNemar’s test.